Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
Learn more: Mount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy studyon May 8, 2024 at 11:18 am
Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- Researchers generate direct measurement of interaction between immune cells and cancer cells from a patient's biopsyon May 7, 2024 at 10:08 am
The pioneering biological research and development measures changes in immune system cells adjacent to cancer cells, providing crucial insights into the patient's immune response and potentially ...
- New mRNA cancer vaccine helps immune system fight deadly brain tumorson May 7, 2024 at 8:23 am
Researchers from the University of Florida have developed a new mRNA cancer vaccine to retrain the body's immune system to attack and potentially treat glioblastoma, a deadly form of brain cancer.
- Study Uncovers a Cause of Cancer Immunotherapy Roadblockson May 7, 2024 at 1:46 am
A study led by Yale scientists, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins.
- Precision medicine tool predicts breast cancer immunotherapy responseon May 6, 2024 at 10:30 am
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
T cells—the body's foot soldiers against invaders, ranging from everyday infections to cancers—are integral to many successful immunotherapies. However, a frustrating factor is that immunotherapies do ...
- Fighting Cancer: A Basic Guide To Checkpoint Inhibitorson May 6, 2024 at 6:30 am
People with cancer may encounter checkpoint inhibitors as a treatment option but may not know where to start. This article can help you learn more.
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
via Bing News